PubMed
An NNMT inhibitor activates oxidative metabolism and reduces obesity in mice
Neelakantan H, Vance V, Wang H, et al. Nat Commun. 2019
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 94% · Mixed 6% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.2 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 86 days · Based on 28 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.2–0.4 mg
Reports span 0.2–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 180 days · Based on 24 repeat reporters
Published sources linked on the 5-Amino-1MQ and Adamax wiki pages.
PubMed
Neelakantan H, Vance V, Wang H, et al. Nat Commun. 2019
PubMed
Heide J, Bilecz AJ, Patnaik S, et al. Nature. 2025
PubMed
Park J, Shin EJ, Kim TH, et al. Archives of pharmacal research. 2024
PubMed
Ashmarin IP, Nezavibatko VN. Neurosci Behav Physiol. 2018
PubMed
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Mol Genet Genomics. 2013